Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 18;48(16):8870–8882. doi: 10.1093/nar/gkaa683

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press on behalf of Nucleic Acids Research.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 5. — Anti-tumor effects of TDN1-EVs delivered Cas9/sgWNT10B gene editing system in vitro, ex vivo and in vivo. (A) Western blot analysis of WNT10B protein expression in HepG2 cells treated by different Cas9/sgWNT10B nanocarriers. (B) Cell growth inhibition was observed after WNT10B knockdown (n = 5). (C) The percentage indel rates in PLOs based on sequencing. (D) Quantification of organoid killing upon different Cas9/sgWNT10B nanocarriers (n = 3). (E) Representative images of the BALB/c nude mice bearing HepG2 xenograft tumors after intravenous injection with different Cas9/sgWNT10B nanocarriers and the xenograft tumors harvested from the mice. (F) The volume growth curves of xenograft tumors from HepG2 tumor-bearing mice during treatment (n = 5). (G) Comparison of the weight of the harvested tumors from the mice after treatment.